249 related articles for article (PubMed ID: 11380399)
1. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.
Fritsche-Polanz R; Jordan JH; Feix A; Sperr WR; Sunder-Plassmann G; Valent P; Födinger M
Br J Haematol; 2001 May; 113(2):357-64. PubMed ID: 11380399
[TBL] [Abstract][Full Text] [Related]
2. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
[TBL] [Abstract][Full Text] [Related]
3. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.
Nagata H; Worobec AS; Oh CK; Chowdhury BA; Tannenbaum S; Suzuki Y; Metcalfe DD
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10560-4. PubMed ID: 7479840
[TBL] [Abstract][Full Text] [Related]
4. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis.
Worobec AS; Semere T; Nagata H; Metcalfe DD
Cancer; 1998 Nov; 83(10):2120-9. PubMed ID: 9827716
[TBL] [Abstract][Full Text] [Related]
5. Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis.
Dror Y; Leaker M; Caruana G; Bernstein A; Freedman MH
Br J Haematol; 2000 Mar; 108(4):729-36. PubMed ID: 10792276
[TBL] [Abstract][Full Text] [Related]
6. Detection of the KIT
Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
[TBL] [Abstract][Full Text] [Related]
7. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia.
Sotlar K; Marafioti T; Griesser H; Theil J; Aepinus C; Jaussi R; Stein H; Valent P; Horny HP
Mol Pathol; 2000 Aug; 53(4):188-93. PubMed ID: 11040941
[TBL] [Abstract][Full Text] [Related]
8. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
Garcia-Montero AC; Jara-Acevedo M; Teodosio C; Sanchez ML; Nunez R; Prados A; Aldanondo I; Sanchez L; Dominguez M; Botana LM; Sanchez-Jimenez F; Sotlar K; Almeida J; Escribano L; Orfao A
Blood; 2006 Oct; 108(7):2366-72. PubMed ID: 16741248
[TBL] [Abstract][Full Text] [Related]
9. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.
Büttner C; Henz BM; Welker P; Sepp NT; Grabbe J
J Invest Dermatol; 1998 Dec; 111(6):1227-31. PubMed ID: 9856847
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.
Akin C; Kirshenbaum AS; Semere T; Worobec AS; Scott LM; Metcalfe DD
Exp Hematol; 2000 Feb; 28(2):140-7. PubMed ID: 10706069
[TBL] [Abstract][Full Text] [Related]
11. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases.
Mimiola E; Bomben R; De Matteis G; Perbellini O; Guglielmelli P; Bonifacio M; Parisi A; Gattei V; Zamò A; Mannelli F; García Montero AC; Zanotti R
Hematol Oncol; 2019 Dec; 37(5):628-633. PubMed ID: 31523839
[TBL] [Abstract][Full Text] [Related]
13. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
14. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
Taylor ML; Sehgal D; Raffeld M; Obiakor H; Akin C; Mage RG; Metcalfe DD
J Mol Diagn; 2004 Nov; 6(4):335-42. PubMed ID: 15507672
[TBL] [Abstract][Full Text] [Related]
15. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
Horny HP; Sotlar K; Sperr WR; Valent P
J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
17. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.
Longley BJ; Metcalfe DD; Tharp M; Wang X; Tyrrell L; Lu SZ; Heitjan D; Ma Y
Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1609-14. PubMed ID: 9990072
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
19. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
